Moreover, the systemic administration of P21 and P22 antibodies in a mouse model of PD significantly reduced α-synuclein pathology, prevented nigrostriatal neurodegeneration, and improved motor function [170]. The gene discussed is SNCA; the disease is Parkinson disease.